FindTrial
Sign In

The 90% effective dose of intravenous remazolam for sedation in children with non-cyanotic congenital heart diseases undergoning computed tomography

The 90% effective dose of intravenous remazolam for sedation in children with non-cyanotic congenital heart diseases undergoning computed tomography

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500098720
Enrollment
Unknown
Registered
2025-03-12
Start date
2023-08-01
Completion date
Unknown
Last updated
2025-03-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Congenital heart disease

Interventions

Intervention group:Remazolam

Sponsors

Shanghai Children’ s MedicaI Center Affiliatcd to Shanghai Jiao Tong University School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
6 Months to 3 Years

Inclusion criteria

Inclusion criteria: 1 Age range of 6 months to 3 years 2 Gender not limited 3 ASA grade I-III 4 Non cyanotic heart disease children scheduled for cardiac CT plain scan and enhanced examination

Exclusion criteria

Exclusion criteria: 1 Contraindications for remifentanil 2 Use of other sedatives within 48 hours prior to examination 3 BMI>30 4 Children with severe liver and kidney dysfunction 5 Other conditions not suitable for testing

Design outcomes

Primary

MeasureTime frame
Ramsay;Heart rate;—

Secondary

MeasureTime frame
Blood pressure;—

Countries

China

Contacts

Public ContactSiyi Zhou

Shanghai Children's Medical Center Affiliated to Shanghai Jiao Tong University School of Medicine

shirley_zsy@126.com+86 136 1196 1010

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026